Navigating the gut–metabolite–immune axis: enhancing efficacy and mitigating toxicity of immune checkpoint inhibitors - Top-Institutions - MDSpire

Navigating the gut–metabolite–immune axis: enhancing efficacy and mitigating toxicity of immune checkpoint inhibitors

  • By

  • Yu Zhang

  • Shengnan Wang

  • Shuang Chang

  • Yuanyuan Li

  • Yexing Dang

  • Zhihao Wang

  • July 13, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, Maryland

    Key Differentiators

    • Oncology

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

Original Source(s)

Navigating the gut–metabolite–immune axis: enhancing efficacy and mitigating toxicity of immune checkpoint inhibitors

  • by Yu Zhang, Shengnan Wang, Shuang Chang, Yuanyuan Li, Yexing Dang, Zhihao Wang

  • July 13, 2026

Related Content

NLRP12 in cancer: a context-dependent regulator of tumor progression, immunity, and metabolism

Leptomeningeal disease (LMD) after resection of brain metastases: results of the multicenter SUBAROMA study

Survival beyond treatment: patterns and determinants of disease-free survival in cervical cancer at a tertiary care center in India